Earnings call Esperion posted its strongest quarter ever, with Q4 revenue up 144% YoY and U.S. net product sales rising 38%. The planned Corstasis acquisition, strong cash position, and imminent U.S.

Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company delivered its “strongest performance to date” in ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with ...

Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to ...

ProtoPie has launched ProtoPie AI in Open Beta, introducing a disruptive "Human-in-the-Loop" workflow that combines AI ...

Dr Ray O’Connor looks at the latest clinical studies on therapeutics, including beta-lockers and potassium sparing diuretics ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Three cryo-EM structures of phosphorylated ...

Shah SJ, Sharma K, Borlaug BA, et al., on behalf of the STEP-HFpEF Trial Committees and Investigators. This was a prespecified analysis of the STEP-HFpEF program with two randomized, ...